Thank you Shellbell for reminding us of the huge potential...

Thank you Shellbell for reminding us of the huge potential PTX100 has treating patients with a minimal safty risk of 4%, this would be very inviting for Prof Miles Prince as l imagine adverse events associated with new drugs in Oncology and in general would be very challenging. l would think we would be very close to treating our first patients. Or we may have already started treating patients at the Freemasons Hospital as it would be a more local cohort. It will be very interesting to receive the results during or later in the year from the UK and the USA, in general my thoughts are that this is a good story for patients followed by shareholders.